Pregled bibliografske jedinice broj: 1171097
Controversies in the treatment of androgenetic alopecia: The history of finasteride.
Controversies in the treatment of androgenetic alopecia: The history of finasteride. // Dermatologic therapy, 32 (2019), 2; 12647-12647 doi:10.1111/dth.12647 (međunarodna recenzija, članak, stručni)
CROSBI ID: 1171097 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Controversies in the treatment of androgenetic
alopecia: The history of finasteride.
Autori
Goren, Andy ; McCoy, John ; Šitum, Mirna ; Dhurat, Rachita ; Kovačević, Maja ; Bolanča, Željana
Izvornik
Dermatologic therapy (1396-0296) 32
(2019), 2;
12647-12647
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, stručni
Ključne riječi
androgenetic alopecia ; finasteride ; sexual dysfunction
Sažetak
Male androgenetic alopecia (AGA) affects up to 60% of men by the age of 50. Currently, there are only two approved drugs for the treatment of male AGA: topical minoxidil and oral finasteride. Topical minoxidil is readily available over the counter and has a well-established safety record. However, following 24 weeks of treatment, less than 40% of men respond to the drug. Additionally, due to the topical route of administration, compliance with minoxidil remains low. In contrast, oral finasteride, a 5-alpha reductase inhibitor, demonstrated efficacy in arresting hair loss in more than 80% of patients following 12 months of treatment. However, controversy surrounding potential adverse sexual side effects has negatively affected public perception of the drug and may significantly reduce the number of patients that can benefit from the drug
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Stomatološki fakultet, Zagreb,
KBC "Sestre Milosrdnice"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE